Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging
Open Access
- 1 March 2018
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 14 (11) , 1460-1469
Abstract
Introduction: Levels of amyloid β peptide 42 (Aβ42), total tau, and phosphorylated tau‐181 are well‐established cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease, but variability in manual plate‐based assays has limited their use. We examined the relationship between CSF biomarkers, as measured by a novel automated immunoassay platform, and amyloid positron emission tomography.Methods: CSF samples from 200 individuals underwent separate analysis for Aβ42, total tau, and phosphorylated tau‐181 with automated Roche Elecsys assays. Aβ40 was measured with a commercial plate‐based assay. Positron emission tomography with Pittsburgh Compound B was performed less than 1 year from CSF collection.Results: Ratios of CSF biomarkers (total tau/Aβ42, phosphorylated tau‐181/Aβ42, and Aβ42/Aβ40) best discriminated Pittsburgh Compound B–positive from Pittsburgh Compound B–negative individuals.Discussion: CSF biomarkers and amyloid positron emission tomography reflect different aspects of Alzheimer's disease brain pathology, and therefore, less‐than‐perfect correspondence is expected. Automated assays are likely to increase the utility of CSF biomarkers.Keywords
Funding Information
- National Institute on Aging (P01AG026276, P01AG03991, P50AG05681)
- Barnes Jewish Hospital Foundation (P30NS098577, R01EB009352, UL1TR000448)
- National Institutes of Health (K23AG053426, R03AG050921)
- NIH (R01AG034119, R01AG053550)
- NIH (P50AG005681, P01AG003991, P01AG026276, UF01AG032438)
- NIH (P50AG005681, P01AG003991, P01AG026276, UF01AG03243807)
This publication has 50 references indexed in Scilit:
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010Journal of Neuropathology & Experimental Neurology, 2012
- Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque PathologyArchives of Neurology, 2011
- Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNIActa Neuropathologica, 2011
- Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer DiseaseArchives of Neurology, 2009
- Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's diseaseEMBO Molecular Medicine, 2009
- Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer diseaseNeurobiology of Aging, 2009
- Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal FluidBiological Psychiatry, 2009
- Prediction and longitudinal study of CSF biomarkers in mild cognitive impairmentNeurobiology of Aging, 2009
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004